Canadian Patents Database / Patent 1249587 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1249587
(21) Application Number: 488887
(54) English Title: ANALGESIC 1,2-BENZISOTHIAZOL-3-YLPIPERAZINE DERIVATIVES
(54) French Title: DERIVES ANALGESIQUES DE 1,2-BENZISOTHIAZOL-3- YLPIPERAZINE
(52) Canadian Patent Classification (CPC):
  • 167/223
  • 260/266.4
(51) International Patent Classification (IPC):
  • C07D 417/12 (2006.01)
  • A61K 31/495 (2006.01)
  • C07D 275/04 (2006.01)
  • C07D 417/04 (2006.01)
  • C07D 417/14 (2006.01)
(72) Inventors :
  • SMITH, DAVID W. (United States of America)
  • YEVICH, JOSEPH P. (United States of America)
(73) Owners :
  • BRISTOL-MYERS COMPANY (United States of America)
(71) Applicants :
(74) Agent: RIDOUT & MAYBEE LLP
(45) Issued: 1989-01-31
(22) Filed Date: 1985-08-16
(30) Availability of licence: N/A
(30) Language of filing: English

(30) Application Priority Data:
Application No. Country/Territory Date
643,614 United States of America 1984-08-23

English Abstract


MJ-592




Abstract

A series of non-oplate analgesics of Formula I


Image


wherein R1 is hydrogen, alkyl, aralkyl, or aryloxyalkyl; R2 is alkyl
or hydrogen; and R3 and R4 are independently selected from hydrogen,
alkyl, acyloxy, alkoxy, alkylthio, halogen, hydroxyl, or trifluoro-
methyl; or a pharmaceutically acceptable acid addition salt.


Note: Claims are shown in the official language in which they were submitted.





WHAT IS CLAIMED IS:

1. A compound of Formula I

Image


or a pharmaceutically acceptable acid addition salt thereof,
wherein
R1 is hydrogen, lower (C1-6) alkyl, either straight chain
or branched, lower alkenyl, lower cycloalkyl, lower
cycloalkyl-lower alkylene, phenyl-lower alkylene,
phenoxy-lower alkylene, phenyl-lower cycloalkyl, or
benzodioxan -2-yl-lower alkylene; with the proviso
that R1 is not hydrogen when R2, R3, and R4
are all hydrogen;
R2 is lower alkyl or hydrogen; and
R3 and R4 are independently chosen from hydrogen, lower alkyl,
lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl.




-35-




2. A compound of claim 1 wherein said proviso is that R1 is not
hydrogen when R2 and R3 are hydrogen and R4 is hydrogen or halogen.

3. A compound of claim 1 wherein R1 contains four or more carbon
atoms.

4. A compound of claim 1 wherein the lower alkyl, lower alkenyl, lower
cycloalkyl, and lower alkylene groups of R1 contain from 4 to 6 carbon atoms.

5. A compound of claim 1 wherein R1 is cycloalkyl.

6. A compound of claim 1 wherein R1 is (C3-6) cycloalkyl.

7. The compound of claim 1, 3-(4-ethyl-1-piperazinyl)-1,2-
benzisothiazole.




-36-


8. The compound of claim 1, 3-(4-methyl-1-piperazinyl)-1,2
benzisothiazole.

9. The compound of claim 1, 3-(4-propyl-1-piperazinyl)-1,2-
benzisothiazole.

10. The compound of claim 1, 3-(4-butyl-1-piperazinyl)-1,2-
benzisothiazole.

11. The compound of claim 1, 3-(4-cyclopentyl-3-methyl-1-
piperazinyl)-1,2-benzisothiazole.

12. The compound of claim 1, 3-(4-pentyl-1-piperazinyl)-1,2-
benzisothiazole.

13. The compound of claim 1, 3-[4-(1-methylethyl)-1-piperazinyl]-
1,2-benzisothiazole.

14. The compound of claim 1, 3-[4-(3-methylbutyl)-1-piperazinyl]-
1,2-benzisothiazole.

15. The compound of claim 1, 3-[4-(2-propenyl)-1-piperazinyl]-
1,2-benzisothiazole.

16. The compound of claim 1, 3-14-(cyclopropylmethyl)-1-
piperazinyl]-1,2-benzisothiazole.


17. The compound of claim 1, 3-(4-cyclopentyl-1-piperazinyl)-
1,2-benzisothiazole.

18. The compound of claim 1, 3-[4-(phenylmethyl)-1-piperazinyl]-
1,2-benzisothiazole.


-37-


- 38 -


19. The compound of claim 1, 3-[4-(2-phenylethyl)-1-piperazinyl]-
1,2-benzisothiazole.

20. The compound of claim 1, 3-[4-(2-phenoxyethyl)-1-piperazinyl]-
1,2-benzisothinzole.

21. The compound of claim 1, 3-[4-(4-phenoxybutyl)-1-piperazinyl]-
1,2-benzisothiazole.

22. The compound of claim 1, 3-[4-[(1,4-benzodioxan-2-
yl)methyl]-1-piperazinyl]-1,2-benzisothiazole.

23. The compound of claim 1, 3-(4-cyclohexyl-1-piperazinyl)-
1,2-benzisothiazole.

24. The compound of claim 1, 3-[4-(2-indanyl)-1-piperazinyl]-
1, 2-benzisothiazole.

25. The compound of claim 1, 3-[4-(1,2,3,4-tetrahydro-2-
naphthyl)-1-piperazinyl]-1,2-benzisothiazole.

26. The compound of claim 1, 3-[4-(2-methylcyclohexyl)-1-
piperazinyl]-1,2-benzisothiazole.



- 39 -

27. A process for preparing a compound of formula I


Image

wherein I

R1 is hydrogen, lower (C1-6) alkyl, either straight chain or
branched, lower alkenyl, lower cycloalkyl, lower cycloalkyl-
lower alkylene, phenyl-lower alkylene, phenoxy-lower alkylene,
phenyl-lower cycloalkyl, or benzodioxan-2-yl-lower alkylene;
with the proviso that R1 is not hydrogen or methyl when R2,
R3 and R4 are all hydrogen;
R2 is lower alkyl or hydrogen; and
R3 and R4 are independently chosen from hydrogen, lower alkyl,
lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl;
said process comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of formula V

Image

V

with a strong chlorinating agent, for example POCl3 or PCl5,so as to yield a
3-chloro-1,2-benzisothiazole compound of formula IV,


- 40 -


Image

IV
wherein R3 and R4 are as defined hereinbefore and wherein A is, for example hydrogen
or t-butyl;

(2) Reacting said compound of formula IV with an appropriate intermediate
compound of formula III

Image

III

wherein R2 is as defined hereinbefore and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a 3-(1-
piperazinyl)-1,2-benziso-thiazole intermediate compound of
formula II

Image

II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to said compound of
formula I.

- 41 -

28. A process according to claim 30, wherein said step 3
is accomplished by alkylating said compound of Formula II with R1X,
wherein R1 is as previously defined and X is a typical leaving group,
for example halide, tosylate, mesylate, and the like, so as to produce
said compound of Formula I.


29. A process according to claim 30, wherein said step 3
is accomplished by subjecting said compound of Formula II to reductive
amination with a carbonyl compound of Formula XX


Image

XX

wherein R5-CH-R6 in its entirety is R1 with R5 being hydrogen, alkyl,
aralkyl or aryloxyalkyl and R6 being alkyl, aralkyl, or aryloxyalkyl so as to
yield a product of formula I

- 42 -

30. A pharmaceutical compound of formula I


Image



or a pharmaceutically acceptable acid addition salt thereof,
wherein

R1 is hydrogen, lower (C1-6) alkyl, either straight chain
or branched, lower alkenyl, lower cycloalkyl, lower
cycloalkyl-lower alkylene, phenyl-lower alkylene,
phenoxy-lower alkylene, phenyl-lower cycloalkyl, or
benzodioxan -2-yl-lower alkylene; with the proviso
that R1 is not hydrogen or methyl when R2, R3 and R4
are all hydrogen;
R2 is lower alkyl or hydrogen; and
R3 and R4 are independently chosen from hydrogen, lower alkyl,
lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl;
for use as a drug for treating patients in need of a non-opiate analgesic effect.


-43-

31. A process for preparing the compound
3-(4-methyl-1-piperazinyl)-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V


with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image

IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;


(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III



- 44 -


Image
III


wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image

wherein R2, R3, R4 and B are as defined hereinbefore; and
(3) Converting said compound of formula II to
the desired compound.


- 45 -

32. A process for preparing the compound
3-(4-propyl-1-piperazinyl)-1,2-benzisothiazole comprising:


(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image


with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image

IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 46 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.

- 47 -

33. A process for preparing the compound
3-(4-butyl-1-piperazinyl)-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image

V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image


IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 48 -


Image
III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 49 -

34. A process for preparing the compound
3-(4-cyclopentyl-3-methyl-1-piperazinyl)-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V


Image

V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image


IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 50 -


Image


III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image


wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 51 -

35. A process for preparing the compound
3-(4-pentyl-1-piperazinyl)-1,2-benzisothiazole comprising:


(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image

IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III



- 52 -

Image


wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 53 -

36. A process for preparing the compound
3-[4-(1-methylethyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V


Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;


(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 54 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image

II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 55 -

37. A process for preparing the compound
3-[4-(3-methylbutyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image

IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 56 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 57 -


38. A process for preparing the compound
3-[4-(2-propenyl)-1-piperazinyl]-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V


Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 58 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 59 -

39. A process for preparing the compound
3-[4-(cyclopropylmethyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 60 -


Image
III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image

II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.

- 61 -

40. A process for preparing the compound
3-(4-cyclopentyl-1-piperazinyl)-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 62 -


Image
III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 63 -
41. A process for preparing the compound
3-[4-(phenylmethyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V


Image

with a strong chlorinating agent, for example POCl3 or PC15,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 64 -



Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 65 -

42. A process for preparing the compound
3-[4-(2-phenylethyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image

IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 66 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 67 -

43. A process for preparing the compound
3-[4-(2-phenoxyethyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III

- 68 -

Image
III
wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.

- 69 -

44. A process for preparing the compound
3-[4-(4-phenoxybutyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image

V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,


Image
IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III

- 70 -



Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II
wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 71 -

45 . A process for preparing the compound
3-[4-[(1,4-benzodioxan-2-yl)methyl]-1-piperazinyl]-1,2-
benzisothiazole comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV

wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 72 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.

- 73 -

46. A process for preparing the compound
3-(4-cyclohexyl-1-piperazinyl)-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 74 -

Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.



47. A process for preparing the compound
3-[4-(2-indanyl)-1-piperazinyl]-1,2-benzisothiazole comprising:

(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 76 -


Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II


Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.

- 77 -


48. A process for preparing the compound
3-[4-(1,2,3,4-tetrahydro-2-naphthyl)-1-piperazinyl]-1,2-
benzisothiazole comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V


Image
V
with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image
IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 78 -


Image
III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II
Image
II

wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


- 79 -


49. A process for preparing the compound
3-[4-(2-methylcyclohexyl)-1-piperazinyl]-1,2-benzisothiazole
comprising:
(1) Treating 1,2-benzisothiazol-3-(2H)-one of
formula V

Image
V

with a strong chlorinating agent, for example POCl3 or PCl5,
so as to yield a 3-chloro-1,2-benzisothiazole compound of
formula IV,

Image

IV
wherein R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen,
hydroxyl, or trifluoromethyl and wherein A is, for example
hydrogen or t-butyl;

(2) Reacting said compound of formula IV with an
appropriate intermediate compound of formula III


- 80 -


Image

III

wherein R2 is lower alkyl or hydrogen and B is hydrogen or
t-butyloxy carbonyl moiety, so as to produce a
3-(1-piperazinyl)-1,2-benzisothiazole intermediate compound of
formula II

Image
II
wherein R2, R3, R4 and B are as defined hereinbefore; and

(3) Converting said compound of formula II to
the desired compound.


Note: Descriptions are shown in the official language in which they were submitted.

~Z~S~37

-- - T --y~
: ~J 592




~NALGESIC 1,2~BENZISOTHIAZOL-
3-YLPIPERAZINE DERIVA~IVES




This lnvention generally pertains to heterocyclic carbon
compounds having drug and bio-affecting propertles and to their
preparation and use. In partlcular, the invention ls concerned with
1,4-dlsubstituted piperazine derivatives wherein one 6ubstituent i6
1,2-benzisothiazol-3-yl, unsub6titueed or substituted in its benzo-
ring; and the other s~b6tituent is, inter alia, alkyl, cycloalkyl,
aralkyl, and phenoxyalkyl.




9~

. - . . i2~587



Related art ~ay be viewed ln light of the ollowlng general
structural Formula 1




in which R and Z are substituent6 and X is a hetero r~ng sto~ or
grouping. The most closely related art appear6 to be that conta~ned
in two issued patents assigned to Bri~tol-Myer~ and CD~pany.
In U.S. Patent 4,411,901, issued on October 25, 1983, to
Temple and Yevich, a ~eries of neuroleptic agents of ~tructure 2 ls
disclo6ed


Z ~ ~ (CH2)n R




wherein Z is hydrogen or halogen and R represent6 the radical:


O O
O ~ ~ alkyl




a b c


_~

d e




-- 2 --

2~ 7



and n i6 3 or 4. As can be 6een, the R- 6ubstituent6 ~-d are hetero-
cycl$c rings, ~hereas lncorporatlon of e and f lnto str~cture 2
produces antipsychotic butyrophenone derivatlves. ~ synthetic
lnter~eaiate compound (3) ~as also disclosed


Z ~


and was claimed ln the related divisional patent V.S. 4,452,799,
issued June 5, 1984.
A series of compounds disclosed as anti-inflammatory agents
by Wade and Risslck in V.S. 4,104,388, lssued August 1, 1978, have
structural formula 4.



-A-B




wherein Y can be C or N; A is a single bond or a 1-4 carbon alkylene
chain; and B is hydrogen, hydroxyl, or optimally wbstituted phenyl.
These compounds are easily distinguished as they are l,l-dioxide ring
derivatives of benzisothiazole.

The following references, ~hile related, are less relevant ~o
the new compounds disclosed in this application.




serupczewski, et al~ In U.S. 4,355,037, lssued ~ctober 19, 19~2,
d~sclosed a 6eries of benzisoxazolyl piperldine derlvative6 (5)
describet as analgetic ~gent~.




SX~


In 6tructure (S), R can be hydrogen, slkyl, alkenyl, cycloalkyl-
alkyl, phenalkyl, hydroxy, aminoalkyl, cyano, cyanoalkyl, alkanolyl,
or a carboxylic acid ester moiety.
Even further removed is a series of benzisoxazole-piperidine
compounds shown as structure 6




which were disclosed 85 antl-psychotics and analgesic6 by Davis and
Klein in ~.S. 4,396,770, issued August 2, lg83.
As can be seen, there is nothing in the foregoi~g references
concerning related art which would suggest or make obvious the compounds
of the present invention.



Summary of the Invention


A series of 1~(1,2-benzlsothiazol-3-yl)piperazine-4-yl
derivatives of Formula I have been synthesized:

~L2~.58~7



,~ r~ ~


wherein ~1 i6 hydrogen, lower (Cl 6) alkyl, either straigh~ chained
or branched, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower
alkylene, phenyl-lower alkylene, phenoxy-lower alkylene, phenyl-lower
cycloalkyl, or benzodioxan-2-yl-lower alkylene; R2 ls lower alkyl or
S hydrogen; and R3 and R4 are independently chosen from hydrogen, lower
alkyl, lower ecyloxy, lower alkoxy, lower alkylthiG, halogen, or
hydroxyl or trifluoromethyl; or a pharmaceutically ~cceptable acid
addition 6alt thereof. Pharmacological testing has demonstrsted that
these compDunds pDssess analgesic activity. Addltionally, the lack
of affinity 6hown for the opioid receptor and intrinsic affinity for
both the serotonergic and adrenergic receptor types in vitro 6uggests
that these compounds may be ~ovel non-opiate anal~es~c agents.




In its broadest aspect, the present invention is concerned
with 1,2-benzisothiszol-3-yl-piperazine derivstive~ having snalgesic
properties characterized by compound of Formula I

R2




3 ~N/~-R

.~4~87



whereln Rl $s hydr~gen, lower (Cl 6) alkyl, elther ~traight chalned
or bFanched, lower alkenyl, lo~er cycloalXyl, lower cycloalkyl-lDwer
alkylene, phenyl-lower al~ylene, phenoxy-lower alkyleDe, phenyl-lower
cycloalkyl, or benzodioxsn-2-yl-lower alkyleDe; R2 ls lower alkyl or
hydrogen; and R3 and R4 are independently chosen from hydroge~, lower
alkyl, lower acyloxy, lower alkoxy, lower alkylthio, halogen, hydroxyl
or trlfluoromethyl; or a pharmaceutically acceptable scid addition
6alt thereof. Rl i6 other than hydrogen when R2, R3 ~nd R4 are all
hydrogen. It is to be understood that, as u6ed herein, halogen
denotes fluorine, chlorlne, bromine, or iodlne. Preferred compounds
of 6tructure I have Rl groups ~ith four or more carbon atoms snd most
preferred compounds sre those in which Rl 1~ cycloalkyl.
It is also to be understood that the present $nvention i6
to be con~idered to include any and all 6teroisomer6 which csn arise
as a consequence of 6tructural asymmetry which would be evident to
one 6killed in the chemical arts. Separation of the individual
6tereo-isomers, should they exlst, would be accomplished by appli-
cation of various methods which are well known to chemical practitioners.
For medicinal use, the pharmaceutically acceptable acid
addition 6alts, those salts in which the anion does not contribute
6igniflcantly to toxicity of pharmacological activity of the organic
cation, may be preferred. The acid addition ~alt6 are obtained
either by reaction of an organlc base of 6tructure I wlth an organic
or inorganic acid, preferably by coneact and ~olutio~ or by any of
2S the standard meth~ds detailet in the literature available to any
practitioner ~killed in the art. Examples of useful organic acids
are carboxylic acids ~uch as maleic scid, acetic acid, tartar~c acid,


~2~3587



propionlc ~cid, fumarlc scid, lsethlonic, succlnic c~d, pamolc Acid,
cyclamic ~cid, pivalic acld, ~nd the like; ~seful ~nor~an~c aclds nre
hydrohal~de aclds such as ~Cl, HBr, ~I; sulfurlc ac~d; phosphoric
~cid; and ~he llke.
~he compounds ~f the instant invention cnn be conveniently
prepsred by use of the processwhlch is 6hown in Scheme 1.
Sche~e 1
Process for Preparatlon of Formula I Compound6


~ ~OC13/PC15~ ~ C1

R4 R R2
V IV ~
Rl~-B

III




R~ R -B
I II


In this scheme, Rl-R4 have the same meanings ~s previously
assigned to them in Formuls I. ~he symbol A can be hydrogen or
t-butyl and B can be hydrogen or a t-butyloxy carbonyl moiety.




. ,

, ~aZ~587



The choice of ~oiety for A ~6 not lmportant in the proce~s ~s lt
is 106t ln the conver~ion of V to IV. When B i6 the t-butyloxy
carbonyl ~oiety ~8 blocking ~roup), it i6 cleaved to give the ~ppro-
priate IV or II compound wherein B 1~ R prior to further react~on,
e.g. reaction with RlX to obtain product I.
Essentially, ehe ~ynthetic process depicted in Scheme 1
comprises:
1) a 1,2 -benzisothiazol -3-(2H)-one, V, is trested with a
Strong chlorinating agent, e.g. POC13 or PC15, to yield a 3-chloro-

1,2-benzisothiazole, lV. The conversion of V to IV by the use of
various halo~enating agents has been adequately described ln the
chemical literature, cf: N. Davls, "Benzisothiazoles" in Advances in
~eterocyclic Chemistry, Vol. 14, Edited by A. R. Xatritzky and A. J.
Boulton, and various references therein.
2) the 3-chloro-1,2-benzisothiazole, IV, is reacted ~lth
an ~ppropriate piperazlne intermediate, III, to give a 3-~1-piperazinyl)-
1,2-benzisothiazDle, II. The reactlon conditions employed for this
step are those which are commonly used for this type of nucleophilic
displacement reaction. If III i6 n liquid, these reactions are often
run neat. For certain intermediate compounds of structure n, yields
may be optimized and isolation of intermediate II made easier by
using an _-t-butyloxy carbonyl piperazine intermediate of III (wherein
B is t-butyloxy carbonyl). In cases such as these, the blocklng N t-
butyloxy carbonyl group is removed from II by acid hydroly~is praor
to its use in the followin~ step. The removal of this blocklng t-
butyloxy carbonyl group occurs readily upon treatment with ethanolic
HCl.


58~7



3~ The 3~ piperazinyl)-1,2-benzi~othiazole, II, 1~
~lkylated wleh Rl~ to afford the desired product of formula I. In
this reaction ~tep the ~nter~edlate II i5 dissolved 1D ~n inert
601vent, preferably acetonltrile, and treated wlth one equivalent ~f
5 8 hlndered baRe, preferably N,N-diisopropylethylamine, followed by
treatment with RlX, wherein X is a typlcal leaving group such as
hallde, tosylate, mesylate, and the llke. ~hls reactlon is usually
complete following heating ~t reflux for 6eversl hour6.
It ~hould be staCed that other 6ynthetic methods in addition
to 6$mple alkylation which, in effect, accomplish the 62me structural
conversion of II bo I, may be employed. An example of such a method
would be reductive amination of compounds of structure Il (B ~ ~) with
a carbonyl compound to yield 8 product of structure I. An cxample of
this alternative synthetic method is shown below.

3 R2


~S~ 0~


¦ NaBH3ClI




(Example 61 in ~able 5)
Various ~ynthet$c methods may be employed for the preparation
of certain formuls V intermediary 1,2-benzisothiazolones when these
are not readily svailsble. Several of these methods are outlined

below ~n Sche~e 2.

_ g _

~24!~ i87


Sche~ne 2
Methvd~ of Preparation for Pormula V Inter~nedlste6
Method 1.
L ~ S~Cl~ ~ co~


VI I VI V

1) NaIo4
2) C13COCCl
Me ~hod 2 . O
~3 R3 R3
~ 1) SOCl~ ~NHt n-BuLi ~ t
R~ ~mine ~ [CH353-2 ~3CH3

X IX VIII

MethDd 3.
1) SOC12
2) t-Butyla~ine

R3 R3 R3
~ 21) n-BuLi ~ [CH3S~2 ~C02~

R4 3r ~ ) Li R4 s~3
XIII XII ~I




-- 10 --


In ~ost in6t~nces, any of the ~ethods shown ln Scheme 2 say
be utlllzed f or prepar~tlon of the desired intermedlate compound V.
Preference of method ls based on svallabil$~y of 6tsrt~n~ c~mpounds
and ease of isolatlon of the various intermediate compo~nds psrticular
S to each meth~d. Method 1 requlres sultably substituted dithiosalicylic
~cldsp Vll, ~hich are then converted to the corresponding acid chlorides, VI,
ln high yield with thionyl chloride. Sequentisl resction of intermediate Vl
with chlorine followed by ammonis affords the desired intermediate
product, V.
Method 2, which is the most general and ~ost widely spplicable
method, begins with an appropriately Eubstituted benzoic acid, X;
which 16 converted to a t-butyl benzamide, IX, by treatment with
thionyl chloride followed by t-butylamine. Thi6 benzamide, IX,
undergoes ortho-metallation with n-butyllithium followed by sulfination
with methyl disulfide to provide compound VIII. Oxidation of the
S-methyl intermediate, VIII, by meta-chloroperbenzoic acid or sodium
perlodate provides the corresponding sulfoxide which is converted to
the desired intermediate product V by treatment with trichloromethyl
chloroformate.
Method 3 i6 a variation of Method 2 which is employed for
preparation of those V compounds when the benzamide iDtermediate,
IX, e.g. 5-methoxybenzoic ac~d, does not undergo the desired regiochemical
~rtho-directed metallation. In this instance, an ortho-bromobenzoic
ncid, XIII, is treated with t-butyllithium and undergoes metal-halogen
exchange to give the ortho-anion, XII, which then reacts with di~ethyl
disulfide ~o yield lntermediate Xl. This ortho-methylehiobenzoic
scid is then converted at this point into intermedlate compound, VIII,
and then on to the final intermediate, V, as shown in Scheme 2.


~ 2~5~'7



Vflrious modifications and ~daptations of ~ethots 1-3
~ould be obv~ous to one akllled in the chemical arts. ExEmples ~f
~ethods 1-3, lncludi~g ~ynehesi~ of pertinent lntermediate~, wlll ~e
exemplified later in the speclfication.
S The compounds of *he in~tant lnvention are useful ~harma-
cologlcal a ents which display anal~esic activity in mammalfi. The
following in vivo test6 (Tsble 1) were used to evaluate and classify
the lnstaDt ~eries of compounds.
Table 1
In Vivo Tests Vsed To ~valuate Formula I Compounds
1. Conditioned Avoidance Response (CAR) -~ Measure of a drug's
tranquilizing actlvity as determined by its atte~uation of
svoidance response to electrical shock in trained fssted rsts.
2. Inhibition of Norepinephrine Lethallty -- Drug inhibition of the
lethslity of the noradrenergic agent norepinephrine indicate6
adrenergic blockade.
3. Vocalization Threshhold -- Measure of a drug's analgesic activi~y
as determined by it6 ability to preven~ electrical 6hock-induced
vocalization in rats.0 4. ~henylquinone Writhing -- Measure of a drug's analgesic activity
as determined by its ability to prevent the writhing syndr~me
induced by phenylquinone ~n mice.
Additionally, the following In vitro radioreceptor binding
asssys were utillzed to determine intrinsic affinlty of compGunds of5 the instan~ series for specific binding sites:

l'.t358~



1. Dopamine blnding in ~triatal t$6sue versus ~3H~sp~perone
2. cl-adrenergic binding ~ersus [3H~B-4101
3. 5erotonin type 2 bindlng in cortlcal ti~sue verRu6
13H]6piperone.
According to the pharmacological profile established by the
aforementioned test6, the instant compounds of ~ormula I possess
analgesic action of 6ufficient potency to render this 6er~es of
compounds promising candidates as non-opiate analgesics. Result6 of
the in vitro binding studies, listed abDve, indicate that adrenerg~c
and serotonergic mechanisms sppear to be involved in mediation of
analgesia for this ~eries.
Concerning the in vivo test data, phenylqui~one writhing
and vocalization threshhold measurements were the main screening
tests utilized as predictive of analgesic activity. Most of the
compounds of the instant series had activities below 10 m~ per kg $n
the vocalization threshhold test ~nd less than 100 mg per kg ln the
phenylquinone writhing test. The conditioned avoidance response and
inhibition of norepinephrine lethality test ~re more predictive of
antipsychotic and sedative actions respectively. Results from ~hese
tests indicate that the instant compounds have low levels of activity
in these tests which may indicate a decreased liability for side
effects.
In summary, the lnstant compounds have pharmacologic
properties suited to their use as non-opiate analgesics. Thus~
snother aspect of the instant invention coDcerns a process for
induclng analgesia in a ma~al in need of such treatment which com-
prises systemic administration to such mammal of an effective analgesic


~Z~ 87



~06e ~f ~ F~rmula I compound or a pharmaceutlcally acceptable acid
addltlon salt thereof. The administratlon and do~age regimens of
compounds of ~ormula I would be expected to be done in the same
manner as for the reference comp~und nefopam (6ee for example,
Heel..et al., Dru~s, 19, pages 249-267 (1980)). Although the dosa~e
and dosage regimen must ~n each case be carefully ~d~usted, utilizing
sound professiDn~l ~udgment and considering the age, ~eight snd
condition of the recipient, the route of administration and the
nature and gravlty of the lllness, generally the dally dose will be
from about 30 to 600 mg adminlstered from 1 to 3 times per day. It
is to be expected that dosage amounts wlll be in the lower part of
this range when given parenterally and in the upper end of the range
when given orally. In some ~nstances, a sufficient therapeutlc
effect can be obtained at lower doses while in others, larger doses
will be required.
The term "systemic ad~inistratlon" as used herein refers to
oral, rectal, and parenteral (i.e., intramuscular, ~ntravenous, and
subcutaneous) routes. Generally, it will be found that when a
compound of the present invention is administered orally, which is
2~ the preferred rouee, a larger quantity of the active agent is required
to produce the same effect as a ~maller quantlty given parenterally.
In accordance with good clinical practice, lt is preferred to sdminister
the instant compounds at a concentration level that will produce
effective analgesic effects without causing any harmful or untoward
side effects. Since the instant compounds are non-opiate analgesics,
not only are ehe typical opiate side effects c~rcumvented, but the
potential exists for concommitant analgesic use of these agenes with
opiate Pnalgesics.




- 14

- ~2~'3~



Therapeutically, the Instant compounds are gener~lly ~iven
as pharmaceutlcal co~po61tions comprlsed of an effective analgesic
~mount of ~ compound cf ~ormula I or a pharmaceutically acceptable
acld addition ~alt thereof ln 8 pharmaceutlcally acceptable carrler.
S Pharmaceutlcal compositlons for effecting fiuch tseat~ent will CGntain
a ma~or or ~inor aDount, from 9S to 0.5% of st least one cDmpound of
the present invention in com~ination with a pharmaceutical carrler,
the carrier comprisiDg one or more solld, semi-solid, or liquid
dlluent, filler and formulAtion ad~uvant which ls non-toxic, lnert
and pharmaceutlcally acceptable. Such pharmaceutic~l compositions
are preferably in dosage unit forms; i.e. physically discrete units
contalning a pre-de~ermined amount of the drug corresponding to a
fraction or multiple of the dose which ls calculated to produce the
desired therapeutic response. The dosage units may contain one or
~ore single doses, or alternatively, one-half or one-third, or less,
of A ~ingle tose. ~ single dose preferably cont~ins an amount
sufficient to produce the desired therapeutic effect upon administration
at one application of one or more dosage units according to the pre-
determined dosage regimen, usually 8 whole, half, or third of ehe
daily dosage administered from one to three times a day. Other
therapeutic agents may also be present. Pharmaceutical co~positions
which provide from about 30 to 600 mg of the actfve ingredient per
unit dose are preferred and are conventionally prepared as tablets,
lozenges, capsules, powders, aqueous or olly suspensions, ByrupS~
elixirs, and aqueous solutions. Preferred oral compositions are in
the form of tablets or capsules and may contain conventional excipienes
such as binding agents ~e.g. yrup, acacia~ gelatin, ~Drbitol,
tra~acanth, or polyvinylpyrrolidone). Fillers (e.g. l~ctose, sugar,




- 15 -

~2~58~



~alze-starch, calclum phosphate, 60rbitol or glycine~, lubrlcant6
ae.g. msgnesium stearaee, talc, polyethylene~lycol or ~llica~,
disiDte~rant6 (e.g. st~rch) and wettin~ agents (e.g. ~odlum lauryl
6ulfste). Solutions or suspensions of a Formula I cvmpo~nd with
S conventional pharmaceutlcal vehicles sre employed for parenteral
composltions ~uch as an aqueous solution for ~ntravenDUS ln~ection or
an ~lly fiuspens$on for lntramuscular in~ectlon. Such compDsit$ons
having the desired clarlty, stability And sdaptability for parenteral
use are obtained by dissolving from 0.1% to lOX by weight of the
active compound in water or a veh~rle consisting of a polyhydric
aliphatic alcohol such as glycerin, propyleneglycol, and polyethylene
glycol6 or mixtures thereof. The polyethyleneglycols cons$st of a
~ixture of non-volat~le, usually l~quid, polyethyleneglycols which
are soluble in both water and organic liquids and ~hich have molecular
weights of from about 200 to 15~0.


Description of ~pecific Embod


The compounds which constieute this inventlon and their
methods of preparatlon will appear more fully from a consideration of
the following examples whlch are given for the purpose of illustration
only and are not to be construed as limiting the invent$on in ~phere
or scope. All temperatures are understood to be ln degrees C when
noe spec~f~ed.
The nuclear magnetic resonance (NMR) spectral characteristic~
refer to chemical shifts ~) expresced ss parts per million ~ppm~
~ersus tetramethylsilane (TMS) as reference standard. The relative

area reported f or the varlous shifts in the proton (NMR) spectral




- 16 -

~L2'~3587


d~ta ~orre~sponds to the number of hydrogen ntoms of a particular
function~l type in the molecule. The nature ~f the ehlfts as to
~ltipllclty ~ reported as broad slnglet tbs)~ ~ingl~t (~), nultlplet
(m), dDublet (d), doublet of doublet6 (dd), or quartet (q). Abbre-

S viations employed are DMSO-d6 (deuterodlmethylsulfoxide), CDC13
(deuterochloroform), and are otherwise conventional. The infrared
(IR) ~pectral descriptions $nclude only absorption wave number6
(cm 1) hsving functional group identlfication value, The DR deter-
minatlons were employed using potassium bromide tKBr) as diluent.
The elemeDtal analyses nre reported as percent by weight.


Synthesis of Intermediates


A. Formula V Compounds




R3 S
R V

EXAM~LE 1
1,2-Benzisothiazol-3(2H)-one (Method 1)
A slurry of 2~2'-dithiosalicylic acid (2017 g, 6.584 moles),
thionyl chloride (1645 g, 13.826 moles), toluene (10 liter) and N,N-
dimethylformamide ~40 mL) was heated at about 75 for 18 hours. At this

polnt all solid had dissol~ed and the resulting dark solution was cooled
to 8. The reaction product crystallized and was isolated by filtration
and washed on ~he filter wieh nbout 1 liter of cold Skelly F. Drying
yielded 1619 g (71~) ~f 2,2'-dithio-bis-benzoyl chloride, m.p. 154-156D
(Lit. m.p. 155-156; cf: I. R. Douglass and B. S. Farrah, J. Or~. Chem.,
26, 351-354 (1961)).


- ~Z~ 37



Chlorine t239 g, 3137 moles) W85 bubbled into a 6tirred
suspenslon of 2,2'-dlthio-bl6-benzoyl chloride tllS7 g, 3.37 ~ole6)
and me~hylene chlorlde (8.46 llter). The resultlng colut~on ~as
added to conc. NH40H (2.89 liter) with vigorous stirr$ng. ~he
S mixture was 6tir-ed for one hour after the addition was co~plete.
Piltratlon yielded a damp solid which was suspended in about 7 liters
of water and acidlfied by ~dding conc. a~ueou6 HCl with vigorous
6tirrlng. The solid was isolated by filtratlon ~nd washed on the
fllter with about 3 liters of water. Drying in vacuo ~t 30D gave
902 g (B~.5~) of product, m.p. 155.5-157.
EXAMPLE 2
General Preparation ~Method 2)
The sppropriate benzoic acid is suspended in chloroform
(1 mL CHC13 per 1 g acid) and ewo drops of DMF. A 6ingle portion
of thionyl chloride (4 mole equiv.) i6 added at room temperature and
the ~esulting mixture 610wly warmed to reflux while being stirred.
The mixture clears a6 the reaction progresses, with ti~es of reflux
typically ranging from 2 to 4 hours. The completed reaction is cooled
to room temperature and concentrated in vacuo to the crude corres-

ponding benzoic acid chlorlde compound in about 95% yield. A methylenechloride solution of the intermediate acid chloride (50 m~ CH~C12
per 0.10 mole acid chloride) is added to a ~olution of triethylamine
and t-butylamine in methylene chloride at oD. The reactlon is
allowed to warm to room temperature and ~tand for approximately lB
hours. The mixture ls then washed with 1.5N HCl, then with 0.5N NaOH
~olution, and flnally with brine. Following washing, the reaction
mixture is dried (MgS04)~ filtered and concentrated in vacuo ~o yield




18 -

. ~ 58'7



the crude ~mide in about 9SX yleld. The amide ~ntermeB~ate ~ cQn
be purlfled by recryst~llizatlon ~r Rugelrohr di~tlllat~on to yield
71-~6~ of purifled product.
The ~enzamlde ~ntermediate (IX; 0.025-0.40 mole) 16 di6solved
la an anhydrous ~HF (500 ~L3 and chllled So -10 ~n an ice/acetone/salt
bath whlle belng ~tirred under a nltrDgen atmosphere. ~o this cold~
6t~rred reaction 601utlon is added n-butyl lithium (2.5 mole equiv.)
at a dropwise rate keeping the temperature at sbout -10~. Following
completion of the addition, the reaction mixture i6 chllled to -78
(try ice/acetone bath) for 15-30 minutes. Freshly distilled dimethyl-
tisulfide (3 mole equiv.) is added dropwise at ~uch ~ rate to keep
the temperature less than _70C. The cold reaction s~lution is ~tirred
one hour and then ~llowed to 810wly warm where, ~t 0, the reaction
is quenched with 15X aqueous NH~Cl solu~ion (2.75 mole equiv.). This
~ixture is concentrated in vacuo and partitioned between methylene
chloride-water. The water layer is further extracted with methylene
chloride and these organic portions combined, dried (MgS04),
filtered, and concentrated in vacuo to the crude thiomethylbenzamide
intermediate (VIII). The crude material which is obtained ln about
90X yield may be used without further purification or may be purified
by flash chromatograplly (hexane/ethyl acetate or hexane/methylene
chlorlde).
The thiomethylbenzamide (VIII; 0.02-0.15 mole) i6 dlssolved
in methanol (200-500 mL) and added to aqueous 0.05N NaI04 (1.15 mole
equiv.) under a nitrogen atmosphere while belng fitirred. The reaction
i5 complete after 20 hours and the methanol ls removed under reduced
pressure. The resulting aqueous phase is extracted wi~h methylene




-- 19 --

, ~249587



chlorlde ~nd these or~anic extr~cts combined and dried (MgS04),
flltered snd concentrated ~n V~CUOr The resultln~ ~olid 1~ purif~d
by flssh chromatDQraphy SethYl acetate) and then dissolved in dichloro-
ethane (0.002 mole per 8 rL) and chllled to 0 ~lth stirring under
nitrogen. Trlchloromethylchloroformate (1 mole equiv.) i6 added n a
~lngle portion while the 601ution is allowed ~o stis ~t room temperature
for about 1 hour. A lOX sod$um hydroxide solution (5 mole equlv.) is
added to the reaction mixture with vigorous 6tirring whieh continues
for up to 2 hours. The mixture is then extracted wlth methylene
chloride, the extract~ combined and dried (MgS04), filtered and
concentrated in vacuo to crude V which may be purified by recrystal~
lization.
EXAMPLE 3
N-t-Butyl-4-methoxy-1,2-benzisothiazoloDe
O-Anisic acid (0.38 mol) was suspended ~n 60 mL CHC13 and
3 drops DMF. A single volume of SOC12 (4 mole equiv.) was added at
room temperature with vigorous reaction and the reaction was then
refluxed. The reaction was monitored by IR for disappearance of the
carboxylic acid carbonyl ~tretch at 1740 cm 1 and appearance of the
acyl carbonyl stretch at 17BO cm 1. The reaction was judged complete
after 24 hours. The solvent and excess reagent were removed via
vacuum distillation (86 mmHg) affording the crude o-anisoyl chloride
in ~95~ ~ield as an oil. The acid chloride was cooled, diluted ~lth
50 mL CHC13 and ~dded dropwise to a chilled (ice/H20) 601ution of TEA
and t-butylamine (1.2 ~ole equiv. each) in 100 mL CHC13. Once addi~ion
was complete, the cooling bath was removed and the mixture 6tood ~t
ambient temperature. The mixture was washed 3 x 1.5N ~Cl, 2 x 0.5N
NaOH, and 1 x brine~ The chloroform was dried on MgS04~ fil~ered,




- 20 -

~7


and concentrated _ v~cuo to approx~ately 93 g oll which ~as
Rugelrohr distllled (110/0.3 mmHg). The N-t-butyl-~-anl6amide wa~
obtained as a yello~ oil ln 95X yleld.
The benzamide ~0.05 mole) was dissolved ln 500 mL anhydrous
THF and chllled to -10 (MeOH/ice) under N2. n-Bu~i (2.5 ~ole equi~.)
was added dropwise nt a rate to keep the temperature beeween -10 and
oD, The soluti~n was 6tirred 30 min. at -~0, then chilled to -75
~C02/acetone) and distilled methyl disulfide (3.0 mole equiv.) was added
at rate to keep the temperature between -75 and -7~. The cold
reaction was ~lowly warmed and at -65 (2.75 mol eqv; 15~ NH4Cl
aqueous solution) was added. The solutlon was concentrated in vacuo;
the residue was partitioned between C~2C12 and water ~nd extracted
3 x CH2C12. The combined organic portions were dried on MgS04, filtered
and concentrated in vacuo to a yellow solld. The crude material was
~udged acceptable by TlC and was used without further purification
~D 94% crude yield.
The thiomethyl benzamide (0.14 mole) was d~ssolved in 200 mL
CH2C12 and 6tirred at -78 (C02/acetone) under N2. A solution of m CPBA
(1.2 mole equiv.) in 700 mL CH2C12 was added dropwise rapidly. The
reaction was judged complete by T~C after 1 ho~lr and was permitted
to warm to ambient temperature. The mixture was concenerated in vacuo,
then par~itioned between CH2C12 and water. The mixture was extracted
3 x ~2 and 3 x 10% aqueous R2C03. The organic layer was dried on
K2C03, filtered and concentrated in vacuo to the crude material which
was flash chromatographed (3% MeOH in CH~C12). The solid was
recrystallized from 10% EtOAc in hexane and the crystalllne sul~oxide
was obtained in 74% yield.




- 2~ -

8~


The ~ulfoxide (~.08 ~ole) was dis601ved ~n 160 ~L of
dlchloroethane and warmed to 40 under h2 Trichlor~methyl chloro-
formate ~1 m~le equiv.) was added neat dropwise. React~on was
vigorous and warming was discontinued while the remai~ing chloro-

formate was added at room temperature. The mlxture was then rewarmedto 70. ~he reactiGn was iud~ed complete by TLC after 1/2 h~ur.
The reaction was coDled and poured into 170 m~ of lOX Na~H (aqueous)
and 6tirred ~igorously 1/2 hour. The dichloroe~hane layer was removed
and the aqueous phase was extracted 3 x CH2C12. The co~bined Qrganic
phases were dried on MgS04, filtered and concentrated in vacuo. The
crude material was flash chromatographed t40% EtOAct60X hexane)
affordlng the N-t-butyl-4-methoxy-1,2-benzisothiazolone in BOX yield.
EXAMPLE 4

S-Methoxy-N-t-butyl-1,2-benzisothiazol-3(2~)-one
(Method 3)
2-Bromo-5-methoxybenzoic acid (0.005 mole) was dissolved in
50 mL of anhydrous tetrahydrofuran and chilled to -78 under nitrogen
with 6tirring. n-Butyllithium (1.1 mole equiv.) was added dropwise
at a rate to keep the temperature less than -70. The yell~w insoluble
anion was then chilled to -115~ (liquid nitrogen-ethyl ether bath)
and t-butyllithium (1.4 mole equiv.) was added at a rate to keep the
temperature less than -85. When addition was complete, the ~ns~luble
dianion was warmed to -75, ~hereupon it became 601uble. Distilled
~ethyl disulfide was added at a rate to keep the reaction temperature
25 less than -70. The bri~ht yellow 601ution turned nearly colorless.
The reaction was 610wly warmed and quenched at -40~ with 15X aqueous
X~4Cl (2.75 mole equiv.). The tetrahydrofuran wa~ remo~ed in vacuo,
and the aqueous phase was washed three ti~es w~th methylene chloride




- 22 -

8'7 - -



~nd the~ ~tcidified wlth 6N HCl, then extracted three times wlth
methylene chloride, dried (MgS04), filtered and conce~trated in vacuo
to ~ white 601id. ~ccording to NMR spectra, the white Colld c~nsi~ted
of a 65:35 wixture of 5-methoxy-1,2-thiomethylbenzoic ~cld and
m-anislc tcld) re~pectively.
Ihe 5-methoxy-1,2-thiomethylbenzoic scid/m-anisic acid
~ixture (0.095 mole calculated as S-methyl n~tterial) was taken up in
80 mL chloroform and two drops DMF. Thlonyl chloride (4 mole equiv.)
was sdded ~tt one time, and the solution heated to reflux. After
refluxing for three hours, the reaction mixture was cooled to room
temperature and concentrated in vacuo to the crude benzoic acid
chloride m$xture which was converted to the benzamide ~ixture by
treatment with t-butylamine as ln Example 2. At this point NMR
indicated that the ratio of S-methyl anisamide to anisamide was
approximately 9:2.
The N-t-butyl-5-methoxy-2-S-methyl benzamidetN-t-butyl
anisamide mixture, used without further purification, (0.04 ~ole
calculated as S-methyl material) was taken up in 450 ml of methanol
and combined with 420 mL of 0.05 M aqueous Nal04 under nitrogen. The
reaction was complete in five hours and the methanol was removed
under reduced pressure. The resulting aqueous phase was extracted
wieh methylene chloride and these orRanic extracts were combined and
dried (M~S0~), filtered and concentrated in vacuo. The resultihg
solid was purified by flash chromatography (ethyl acetate) to give
the solld ~ulfoxide intermediaee in approximately 76Z yield.




- 23 -

- ~24~58t7
.



~he N-t-~utyl 5-methoxy-2-S-methyl sulfoxide benzamide was
then tre~ted with trlchloromethylchloroformate us~ng the pr~cedure
glven ~n Example 2 to yield 3-methoxy-~-t-butyl-1,2-benzisothiazol-
3(2H)-one, m.p. 92-94~.
other substituted benzisothiszolones, which can be prepared
by the general 6ynthesis of Method 2 are 6hown in Table 2.
Table 2
5ubstituted Benzisothiazolones
R3 o
R ~ N-t-Bu


Example No. R3 R4 m.p.
-
10 5 4-~eO H 141-143
6 M 6-MeO 60-63
7 H 7-MeO 118-120
H 6-C1 115-123D
9 4-SCF3 H
lS10 H 6-SCF3
11 H 7-SCF3
12 4-OH H
2 3
14 H 6-0~
~015 2 3
16. 4-CF3 H
17 H 6-CF3
18 ~ 7-CF3




- 24 -

- ~2'~958'7



B. ~ormula IV CDmpounds




IV


EXAMPLE 19
3-Chloro-1,2-benzisothiazole
A mixture of 1,2-benzl60thiazole-3(2H)-one (Example 1,
818 g, 5.414 ~oles) snd POC13 (1114 g, 7.26 moles~ was heated to 120D
over about two hours. HCl evolution began at about 70. Heat was
continued at 120 for another 1.5 hours. The hot ~olution was poured
into 8 llter of H20 at 25. The temperature was not allowed to
exceed 50. After 30 minutes, the mixture was cooled to 25~ (ice
addition) and extracted with methylene chloride (4 liter). A dark
oil was obtained by evaporation of the methylene chloride in vacuo.
This oil was extracted with Skelly B (3 X 1 liter and 2 x 500 ml).
The turbid extract was treated with Darco G-60 (30 g) ~nd Gelite A-545
(20 8) before filtering. The filtrate was evaporated in vacuo to
15 give 743.9 g, 81~, of a yellow oil which readily crystallized.
Distillation of the oil at reduced pressure gave 707 g, 77X, ~.p.
80-85 at 0.75 Torr., of colorless distillate which readily crystallized,

.p. 39-41.




- 25 -

' 12~58~


EXAMPLE 20

Substituted 3-Chloro-1,2-~enzlsothia201e~
(General Method)
The benzi~othiazolone was dlssol~ed in dichloroethane
(0.04 ~ole/100 ml,) and ~C15 was ~dded. The mixture ~as refluxed while
monitoring the progress of the reaction by TLC. If the re~ction was
~udged incomplete ~fter one hour at reflux, ~n additional 0.1~0.5 mole
equiv. of PC15 was ~dded and refluxed continued until ehe ctarting
~aterial was consumed. The reaction was cooled, ~nd ~olvPnt and excess
reagent were removed by distillatlon under reduced pressure. The resldue
was flash chromatographed (hexane/methylene chloride) affording the
product BS a sol~d.
EXAMPLE 21
3-Chloro-4-methoxy-1,2-benzisothiazole
The 4-methoxy benzisothiazolone (0.065 ~ole) was dissolved in
200 ~L of dichloroethane and PC15 (1.05 mole equiv.) was added neat. The
reactloD was refluxed-monitored by tlc. An additional ~.25 mole equiv.
and 2 x 0.10 mole equiv. of PC15 was ~dded after 1 hour, 2-1/2 hours,
and 3 hours before the reaction was Judged complete by tlc. The reaction
was cooled and the solYent and excess reagent removed by house vacuum
distillation. The residue was flash chromatographed (30Y. CH2C12/70%
hexane) affording the 3-chloro-4-methoxy-1,2-benzisothiazole in 60%
yleld.
Some other examples of substltuted 3-chloro-1,2-benzisothiazoles
which can be prepared via the general method of Example 20 sre shown in
Table 3.




- 26 -

124~


~ble 3
Substituted 3-Chlorobenzi60thiazole6
R3




Cl


. IV

Ex. R3 R4 Yield (%) ~.P. ~ C?
22 4-C1 7-MeO - -
5 23 H 7-MeO
24 H 6-MeO 94 80-83
H 6-C1 95 99-101
2S 4-MeO H 98
27 5-MeO ~ - _
~ 28 5-OH H
29 5-~eO 6-Cl - -
5-MeO 6-MeO - -




- 27 -

~2~3~



C. ~ormula III Compounds
R2




!t~ N-B
\J

III


EXAMPLE 31
t-Butyloxycarbonylpiperazine
Benzylpiperazine (0.15 mole) and pulverized K2C03 (0.62 mole
equlv.) were combined in 200 mL of 1:1 dioxane/water and mechan~cally
6tirred while cooling to 0~. ~he pyrocarbonaee (1.12 mole equiv.) was
~dded, and the reaction was stirred one hour in the cold and then 18 hr
~t ambient temperature. The dioxane was removed in vacuo and the
aqueous phase was extracted (3 X methylene chloride), dried ~MgS04),
filtered and concentrated in vacuo to ~n oil in about 95Z crude yield.
The oil was d$vided into two e~ual portions snd each was dissolved in
warm absolute ethanol (150 mL), glacial acetic acid (2.1 mole equiv.)
and combined with 4.1 g palladium-on-carbon cataly~t ln a Parr hydro-
genation bottle. The mixture was hydrogenated at an inltial ~2
pressure of ca. 55 psi until the theoretical amount of hydro~en had
been consumed. Ihe mixture was filtered through celite and rinsed wlth

generous amounts of ~bsolute ethanol, then concentrated to the solld
product ln 84X yield.
Use of this procedure employing benzylpiperazlnes with appro-
priate substitution on the piperazine ring will yield ~he desired t-
butyloxycarbonylpiperazines where R is other than hydrogen.




- 28 -

,lZ~3~



D. Formula I~ Compounds
R2




~ ~ -B



R
II



EXAMPLE 32
1-~1,2-Benzisothiazol-3-yl)piperazlne
A 4L suction flask was charged with anhydrous piperazine
5 (1582 g, 18.36 moles) followed by molten 3-chloro-1,2-benzisothiazole
(Example 8, 622 g, 3.672 moles). The flask was stoppered with a
wired-on rubber stopper and a short length of pressure tubing was
~ired-on to the ~ide tube. The flask was evacuated (house vacuum)
and the pressurc tubing on the side arm clamped ~hut. The apparatus
was then oven heated at 125 with occas$onal swirling as melting
proceeded. After 24 hours at this temperature, the orange melt was
quenched in 4.8 liter of cracked ice and water. One equivalent of

50X NaO~ (293 g, 3.672 moles) was added in one portion. The mixture
was extracted with methylene chloride and these extracts washed with
lS water. Concentration in vacuo gave 734 g of crude product w~ich was
recrystallized from 1800 mL of boil~ng ethyl acetate to yield 548 g,
68%, m.p. 88-90.




- 29 -

5~37



E~AMPLE 33
Substltuted 3~ Plperazlnyl~-1 t 2-benzisothiazoles
~ hls synthesls proceeds via the 3-(t-butyloxy carbonyl
piperaz~ne)-benzi60thia201e intermediate with subsequent removal of the
t-BOC protectlve group.
~ -Butyloxycarbonylpiperazine tExample 15, 2.5 mole equlv.) was
dissolved ln anhydrous tetrahydrofuran (0.01-0.02 ~ole/90 ~L) ~nd
chilled to -78 under nitrogen wlth st~rring. n-Butyl llthium (2.5
mole equiv.~ was added at a rate to keep the temperature le~s than
_70D. The 3-chloro-1,2-benzisothiazole in tetrahydrofuran (1 mole
equiv./60 mL) was added dropwise to keep the temperature less than
-70. ~hen the edditlon was complete, the solution WhS warmed to 0
and then quenched with 15% ~queous NH4Cl (2.75 mole equiv.). Following
concentration in vacuo the residue was extracted with methylene chloride
and the extract was washed with 0.5N ~Cl, drled (MgS04), fil~ered and
concentrated in acuo to B semi-solid which was flash chromatographed
(hexane/ethyl acetate). These 3-(_-B~C plperazine~ benzisothlazole
intermediates were generally obtained in 73 to 90X yield.
To remove the _-BOC protective group, the appropriate t-B~C
piperazinylbenzisothiazole was taken up in a minimal amount of ~arm
absolute ethanol and scidified with 5N ethanolic HCl (5 mole equlv.),
then heated to 90 for 1/2 hour. Upon cooling, the ~olvent was removed
_ vacuo and the crude product recrystalllzed from absolute ethanol and
obtained in yields ranglng from 40-60X.




- 30 -

5~7



EXAMPL~ 34
4-Methoxy-1~_2-benzisothia ol-3-yl Plperszine Hydrochlorlde
t-ButylDxycarbonylpiperazine (O.04 mole) w~s di6601ved ~n
150 ml of ~nhydrou6 eetrahydrofuran and chilled to -~8~ under nltrogen.
n-BuLl (0.04 mole) wa~ ~dded at a rate to keep the temper~ture less
than -65~. After 10 minutes, the 4-methoxy-3-chloro-1,2-benzi~othiazole
(0.016 mole~ ln 60 ~L tetrahydrofuran was sdded dropwise keeping t ~-70.
The reaction was monitored by tlc and ~udged complete ~mmedistely. The
ice bath was removed and 15X aqueous NH4Cl (0.044 mole) was ~dded.
The mixture was concentrated in vacuo and the residue taken up ln CH2C12
and washed 1 x H20 nnd 1 x cold 0.5N HC1. The methylene chlorlde was
drled on MgSO~, filtered and concentrated $n V8CUO to the crude pr~duct
which was flash chromatographed (3:1 hexane/EtOAc) affording the deslred
material in 73X yield.
The butyloxycarbonylpiperazine benzisothiazole (0.012 mole)
wa~ taken up ln warm absolute ethanol and acidified with eehanolic HCl
(5 mole equ~v.). The 601ution was stirred 30 minutes ~t 90~ The
mixture was cooled and the 601vent removed in vacuo. The crude 601id ~as
recrystallized from absolute EtOH affording 4-methoxy-1,2-benzisothiazol-
3-yl-p~perazine bydrochloride in 62% yield.
Examples of additional products which may be vbtained using
the procedure of Example 33 are 6hown in Table 4.


- ~4'3~1~37



T~bl~ 4

Substituted Formula 1 3~ plperazinyl)-
benzi~othla201es (as HCl ealtfi)
R3




~ J ~ ~ . HCl


Ex. R3 - R4 Yleld (X) m.p. (
~ 7-MeO 40 2B6-290
36 4-C1 7-Me~ 37 271-274
37 H 6-MeO 43 246-250
38 4-Me H 62 240-247
39 5-MeO 6-MeO
5-MeO 6-Cl
41 4-CF3 H


Synthesis of Products


EXAMPLE 42

3-(4-Ethyl-l-piperazlnyl)-1,2-benzisoth$azole
To 3-(l-piperaziDyl)-1,2-benzi6othiazole (5.0 ~, 0.023 mole)
in 25 ~L of acetonitrile was added N,N-diisopropylethylam$ne (3.2 g,
0.025 mole) and bromoethane (2.6 g, 0.024 mole) at 20~ The mixtu~e was
refluxed for approximately 3 hr and theo concentrated in vacuo; taken
up in 5X aqueous R2C03, and flashed chromatographed with 5% ~ethanol/
methylene chloride. The fraction6 were concentrated ~n vacuo to yield
4.6 g (0.02 mole, 81X) of an oily product. Thi6 product cil was con-
verted ~o the sol~d hydrochloride ~alt by treatment of ~n ethanol




- 32 -





solution with ethanolic HCl. Recrystalll2ation from eth~nol ~ave
whlte solid, ~.p. 230-232~.
Anal. Calcd. for C13H17~3S-HCl-H20: C, 51.90; ~, 6.3~;
N, 13.97. Found: C, Sl.65; X, 6.60; N, 14.15.
Using the procedure of Example 22, or ~D appropriate modifi-
cation thereof, the ~ndivldual compounds of Formula I can be readily
prepared. Additional examples of these ~ompounds are hown 1D Table 5.

,95~37


T~ble 5
~r~ul~ I C~mp~unds




~x. R R2 R3 R4 Formuls m.p. (C)
43 -CH3 H H H C12H15N3S 250-252
44 -(Q2)2CH3 H H H C12H21N4S~HC1222-224
-(C~2)3CH3 H 15H15 3 209-211
46 ~ 3-Me H H C17R23N3S~HC198-100
47 ( 2)4 3 H H H 16 23 3 203-204
48 CH(CH3)2 R H H C14H19~3S 260-263
: 10 49 -(CH2)2CH(CH3)2 H H H C16H23N3S HCl231-233
-CH2CH-CH2 H H H C14H17N3S~HC1215-217
51 -C~2~ H H 15 19 3 243-244
52 ~ H H H C16H21N3S 0.1 ~2134-135
53 -CH2Ph ~ H H ~18H19N3S H 1226-228
54 ( 2) 3 H H 19 21 3 107-109
-(CH2) 2~Ph ~ H 19~21N3
56 ( 2~40P H H H C2lH25N3os~Hcl181-182

57 -CH2~ H H H C20H21N32S'HC1206-220

58 ~ H H H C17~23N3S 98-100
S3 ~ H H H C18~25N3S ~Cl280-290

60 ~ H. H H 20 21 3~ 139 141
61 ~ H H H 21H23 3 114-118
62 ~'~ 2-Me 5-~eO 6-C1
S3 ~ H H 6-CF3

- 34 -

Sorry, the representative drawing for patent document number 1249587 was not found.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Admin Status

Title Date
Forecasted Issue Date 1989-01-31
(22) Filed 1985-08-16
(45) Issued 1989-01-31
Expired 2006-01-31

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Filing $0.00 1985-08-16
Current owners on record shown in alphabetical order.
Current Owners on Record
BRISTOL-MYERS COMPANY
Past owners on record shown in alphabetical order.
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.

To view selected files, please enter reCAPTCHA code :




Filter Download Selected in PDF format (Zip Archive)
Document
Description
Date
(yyyy-mm-dd)
Number of pages Size of Image (KB)
Drawings 1993-10-05 1 10
Claims 1993-10-05 46 741
Abstract 1993-10-05 1 11
Cover Page 1993-10-05 1 19
Description 1993-10-05 34 981